CASE.EDU:    HOME | DIRECTORIES | SEARCH
case western reserve university

THE LANDRETH LAB

 

GARY LANDRETH, Ph.D.

Publications (Since 2005)

Cordle, A. and Landreth, G. HMG-CoA reductase inhibitors attenuate Ab-induced microglial inflammatory responses. J. Neurosci. 25:299-307, 2005.

Grommes, C., Landreth, G.E., Schlegel, U. and Heneka M.T. The non-thiazolidinedione tyrosine-based PPARgamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J. Pharmacol. Exp. Ther. 313:806-813, 2005.

Heneka, M., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O’Banion, K., Klockgether, T., Van Leuven, F. and Landreth, G. Acute treatment with the PPARg agonist pioglitazone and ibuprofen reduces glial inflammation and Ab1-42 levels in APPV717I transgenic mice. Brain 128:442-453, 2005.

Nekrasova, T., Shive, C., Gao, Y., Kawamura, K., Guardia, R., Landreth, G. and Forsthuber, T.G. ERK1-deficient mice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. J. Immunol. 17:2374-2380, 2005.

Koenigsknecht, J. and Landreth, G. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25: 8240-8249, 2005.

Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A. and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 380:34202-34209, 2005.

Schutz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G,E, Schurmann, B., Zimmer, A. and Heneka, M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 25:7805-7812, 2005.

Sastre, M., Dewachter, I., Rossner, S., Bogdanovic,  B., Rosen, E., Borghgraef, P., Evert, B., Dumitrescu-Ozimek , L., Thal, D., Landreth, G., Walter, J., Klockgether , T., van Leuven, F. and Heneka, M.  Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. 103:443-448, 2006.

Grueter, B., Olsen, C., Schrammsapyta, N., Gosnell, H., Nekrosova, T., Landreth, G. and Winder, D.. ERK1-dependent mGluR5-induced LTD in the bed nucleus of the stria terminalis is disrupted by cocaine administration. J. Neurosci. 26:32310-32319, 2006.

Wilkinson, B., Koenigsknecht-Talaboo, J., Grommes, C., Lee, C.Y. and Landreth, G. Fibrillar beta-amyloid stimulated intracellular signaling cascades require vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 281:20842-20850, 2006.

Grommes, C., Landreth, G.E., Sastre, M., Beck, M., Feinstein, D.L., Jacobs, A.,H., Schlegel, U. and Heneka, M.. Inhibition of in vivo glioma growth and invasion by PPARgamma agonist treatment. Mol Pharmacol. 70:1524-33, 2006.

Victor, N.A., Wanderi, E.W., Gamboa, J., Zhao, X., Aronowski, J., Deininger. K., Lust, W.D., Landreth, G.E. and Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24:1653-1663, 2006.

Limpert, A., Karlo, C.and Landreth, G. NGF stimulates the concentration of TRkA within lipid rafts and ERK activation through the CAP adapter protein. Mol. Cell. Biol. 27:5686-5698, 2007.

Zelcer ,N, Khanlou ,N, Clare, R, Jiang, Q, Reed-Geaghan, EG, Landreth, GE, Vinters, HV, Tontonoz, P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci 104:10601-10606, 2007.

Ostrowski, S, Wilkinson, B, Golde, T and Landreth, G. Statins reduce amyloid beta production through inihibition of protein isoprenylation. J. Biol. Chem. 282:26832-26844, 2007.

Grommes C, Lee CY, Wilkinson BL, Jiang Q, Koenigsknecht-Talboo JL, Varnum B, Landreth GE. Regulation of Microglial Phagocytosis and Inflammatory Gene Expression by Gas6 Acting on the Axl/Mer Family of Tyrosine Kinases. J Neuroimmune Pharmacol. 3: 130-140, 2008.

Engel S.R., Creson T.K., Hao Y., Shen Y., Maeng S., Nekrasova T., Landreth G.E., Manji H.K. and Chen G. The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry epub Jan 29, 2008.

Jiang, QJ, Lee, C.Y., Wilkinson, B, Cramer, P., Mandrekar, S., Lamb, B, Smith, J.D., Holtzman, D.,Tontonoz, P. and Landreth, G. ApoE promotes the proteolytic degradation of Abeta. Neuron, 12:681-693, 2008. PMID: 18549781

Samuels , I.S., Karlo, J.C., Faruzzi, A.N., Pickering, K., Herrup, K., Sweatt, J.D., Saitta ,S.C. and Landreth, G.E. Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci. 28:6983-6995, 2008. PMID: 18596172

Newbern J, Zhong J, Wickramasinghe RS, Li X, Wu Y, Samuels I, Cherosky N, Karlo JC, O'Loughlin B, Wikenheiser J, Gargesha M, Doughman YQ, Charron J, Ginty DD, Watanabe M, Saitta SC, Snider WD, Landreth GE.Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. Proc Natl Acad Sci 105:17115-20, 2008. PMID: 18952847

Mandrekar, S., Jiang, Q., Lee ,C.Y., Koenigsknecht-Talboo, J., Holtzman, D.M. and G.E. Landreth. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 29:4252-4262, 2009.

Engel, S.R., Creson, T.K., Hao ,Y., Shen, Y., Maeng, S., Nekrasova, T., Landreth, G.E., Manji, H.K,. and G. Chen. The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry. 14:448-1461, 2009.

Bliss SP, Miller A, Navratil AM, Xie J, McDonough SP, Fisher PJ, Landreth GE, Roberson MS. ERK signaling in the pituitary is required for female but not male fertility. Mol Endocrinol. 23:1092-101, 2009

Reed-Geaghan, E, Savage, J. Hise, A and Landreth, GE. CD14 and Toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglia activation . J. Neurosci. In Press, 2009.

Matsushita T, Chan Y, Kawanami A, Balmes G, Landreth GE, and S. Murakami. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol. 29:5843-5857, 2009. PMID: 19737917

Heffron, D., Landreth, G., Samuels, I, and JW Mandell.Brain-Specific Deletion of Extracellular Signal-Regulated Kinase 2 Mitogen-Activated Protein Kinase Leads to Aberrant Cortical Collagen Deposition. Am J Pathol. 175:2586-2599, 2009. PMID: 19893051

Srinivasan, R., Zabuawala, T., Huang, H., Zhang, J., Gulati, P., Fernandez, S., Karlo, J., Landreth, G., Leone, G., M C. Ostrowski. Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. Plos One, 4:e8283, 2010. PMID: 20011539

Geldmacher, D., Fritsch, McClendon, M.J. and G. Landreth. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer’s disease. Arch Neurol. In Press, 2010.

Gold, M., Alderton. C., Zvartau-Hind, M., Egginton, S., Saunders, A., Irizarry, M., Craft, S., Landreth, G., Linnamägi, U. and Sawchak, S. Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. Dementia and Geriatric Cognitive Disorders 30:131-146, 2010. PMID: 20733306

Wilkinson, B, Cramer, P, Varvel, N, Reed-Geaghan, E, Jiang, Q., Szabo, A., Herrup, K.,, Lamb, B. and Landreth, G. Ibuprofen attenuates oxidative damage through inhibition of microglial NOX2 in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Aging, epub Aug. 7, 2010. PMID: 20696495

Gamboa J, Blankenship D, Niemi JP, Landreth GE, Karl M, Hilow E, Sundararajan S. Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Neuroscience170:-846-857, 2010. PMID: 20691766

Alter, B.J. , Zhao, C., Karim, F., Landreth G.E. and Gereau, RW. Genetic targeting of ERK1 suggests a predominant role for ERK2 in murine pain models. J. Neurosci. 30:11537-11547, 2010.

Reed-Geaghan, EG, Savage, JC, Hise, AG, Landreth, GE. CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation. J Neurosci. 29:11982-92, 2009. PMID: 19776284

Geldmacher, D., Fritsch, McClendon, M.J. and Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer’s disease. Arch Neurol. In Press, 2010. PMID: 20837824

Reed-Geaghan, E., Geaghan, Q., Cramer, P., and Landreth, G. Deletion of CD14 attenuates AD pathology by influencing the brain’s inflammatory milieu. J. Neurosci. 30:15369-15373, 2010.

Sebastian A, Matsushita T, Kawanami A, Mackem S, Landreth GE, Murakami S. Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal. J Orthop Res. 2010.

Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci. 31:843-50, 2011. PMID: 21248107

Newbern JM, Li X, Shoemaker SE, Zhou J, Zhong J, Wu Y, Bonder D, Hollenback S, Coppola G, Geschwind DH, Landreth GE, Snider WD. Specific Functions for ERK/MAPK Signaling during PNS Development. Neuron. 69:91-105, 2011.

Portillo JA, Okenka G, Reed E, Subauste A, Van Grol J, Gentil K, Komatsu M, Tanaka K, Landreth G, Levine B, Subauste CS. The CD40-Autophagy Pathway Is Needed for Host Protection Despite IFN-G-Dependent Immunity and CD40 Induces Autophagy via Control of P21 Levels. PLoS One. 2010 Dec 31;5(12):e14472

Kyono A, Avishai N, Ouyang Z, Landreth GE, Murakami S. FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. J Bone Miner Metab. [Epub ahead of print] 2011 PMID: 21678127

Lee, C.Y., Tse, W. and Landreth, G. Apoe E promotes Ab trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. In Press, 2011. PMID:22130662

Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's ß-amyloidosis mouse model. J. Neurosci. 31:15692-15671, 2011 PMIC:22049439

Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's ß-amyloidosis mouse model. J Neurosci.31:15962-15971, 2011. PMID: 22049439

Refereed Reviews:

Sundararajan, S., Jiang, Q., Heneka, M. and Landreth, G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Intl. 49:136-144, 2006.

Landreth, G. Therapeutic Use of Agonists of the Nuclear Receptor PPARgamma in Alzheimer's Disease. Curr. Alz. Res. 4:159-164, 2007.

Wilkinson, B.L. and Landreth, G. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflam. 3:30-42, 2006.

Jiang, Q., Mandrekar, S. and Landreth, G. The role of PPARgamma in Alzheimer’s Disease. CNS Drugs, In press, 2007.

Heneka, M. and Landreth, G. PPARs in the Brain. Biochem. Biophy. Acta, 1771:1031-1045, 2007.

Heneka, M., Landreth, G and M. Hull. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol. 3:496-504, 2007.

Jiang, Q, Heneka, M. and G. Landreth. The Role of Peroxisome Proliferator-Activated Receptor-gamma (PPARgamma) in Alzheimer's Disease : Therapeutic Implications. CNS Drugs 22:1-14, 2008.

Landreth, G., Jiang, Q., Mandrekar, S. and Heneka, M. PPARgamma Agonists as Therapeutics for the Treatment of Alzheimer's Disease. Neurotherapeutics 5:481-489, 2008.

Samuels, I., Saitta, SC. and G. Landreth. MAPing CNS cognition and development: An ERKsome process. Neuron 61:160-167, 2009.

Landreth GE, Reed-Geaghan EG. Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol. 336:137-53, 2009.

Cameron, B. and G. Landreth. Inflammation, microglia and Alzheimer’s disease. Neurobiol. Dis. Neurobiol. Dis. 37:503-509, 2010. PMID: 19833208

Mandrekar-Colucci, S. and G. Landreth. Microglia and inflammation in Alzheimer’s Disease. CNS Neurol. Disord. Drug Targets 9:157-167, 2010.

Lee, C.Y. and G. Landreth. The role of microglia in amyloid clearance from the AD brain. J. Neural Trans. 117:949-960, 2010. PMID: 20552234

Newbern JM, Li X, Shoemaker SE, Zhou J, Zhong J, Wu Y, Bonder D, Hollenback S, Coppola G, Geschwind DH, Landreth GE, Snider WD. Specific Functions for ERK/MAPK Signaling during PNS Development. Neuron 69:91-105, 2011.

Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH. The ERK2 Mitogen-Activated Protein Kinase Regulates the Timing of Oligodendrocyte Differentiation. J Neurosci. 31:843-50, 2011.

Sundararajan, S. and Landreth, G. Antiinflammatory properties of PPARgamma agonists following ischemia. Drug News Perspect. 17:229-36, 2004.

Sundararajan, S., Jiang, Q., Heneka, M. and Landreth, G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Intl. 49:136-144, 2006.

Landreth, G. Therapeutic Use of Agonists of the Nuclear Receptor PPARgamma in Alzheimer's Disease. Curr. Alz. Res. 4:159-164, 2007.

Jiang, Q., Mandrekar, S. and Landreth, G. The role of PPARgamma in Alzheimer’s Disease. CNS Drugs, In press, 2007.

Heneka, M. and Landreth, G. PPARs in the Brain. Biochem. Biophy. Acta, 1771:1031-1045, 2007.

Heneka, M., Landreth, G and M. Hull. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol. 3:496-504, 2007.

Jiang, Q, Heneka, M. and G. Landreth. The Role of Peroxisome Proliferator-Activated Receptor-gamma (PPARgamma) in Alzheimer's Disease : Therapeutic Implications. CNS Drugs 22:1-14, 2008.

Landreth, G., Jiang, Q., Mandrekar, S. and Heneka, M. PPARgamma Agonists as Therapeutics for the Treatment of Alzheimer's Disease. Neurotherapeutics 5:481-489, 2008.

Samuels, I., Saitta, SC. and G. Landreth. MAPing CNS cognition and development: An ERKsome process. Neuron 61:160-167, 2009

Invited Commentary

Mrak, R. and Landreth, G. PPARgamma, neuroinflammation, and disease. J Neuroinflamm. 1:5-7, 2004.

Landreth, G. PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp. Neurol.199:245-248, 2006.

Landreth, G. The immunology of Alzheimer's disease: prospects towards harnessing disease mechanisms for therapeutic ends. J. Neuroimmune Pharm. 2: 131-133, 2007.

Morgan D, Landreth G, Bickford P. The promise and perils of an Alzheimer disease vaccine: a video debate. J. Neuroimmune Pharmacol. 1:1-3, 2009.